WO1996026219A1 - Sequence d'adn isolee destinee a un nouveau recepteur de macrophage a domaine collagene et chaine polypeptidique codee par cette sequence - Google Patents

Sequence d'adn isolee destinee a un nouveau recepteur de macrophage a domaine collagene et chaine polypeptidique codee par cette sequence Download PDF

Info

Publication number
WO1996026219A1
WO1996026219A1 PCT/FI1996/000091 FI9600091W WO9626219A1 WO 1996026219 A1 WO1996026219 A1 WO 1996026219A1 FI 9600091 W FI9600091 W FI 9600091W WO 9626219 A1 WO9626219 A1 WO 9626219A1
Authority
WO
WIPO (PCT)
Prior art keywords
marco
domain
sequence
couagenous
isolated
Prior art date
Application number
PCT/FI1996/000091
Other languages
English (en)
Inventor
Karl Tryggvason
Outi Elomaa
Maarit Kangas
Original Assignee
Karl Tryggvason
Outi Elomaa
Maarit Kangas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karl Tryggvason, Outi Elomaa, Maarit Kangas filed Critical Karl Tryggvason
Priority to AU47196/96A priority Critical patent/AU4719696A/en
Publication of WO1996026219A1 publication Critical patent/WO1996026219A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Definitions

  • the present invention is directed to a method for isolating and identifying the nucleotide sequence for a novel macrophage receptor with a coUagenous domain, termed "MARCO".
  • the invention relates to the nucleotide sequence for MARCO identified by the process of the invention and the isolated and purified polypeptide chain encoded by such a nucleotide sequence.
  • the invention also provides for the use of the identified nucleotide sequence (or fragments thereof) to detect the gene or its parts, or its mRNA transcript in tissue, cell or fluid samples in normal or pathological situations.
  • the invention relates to the production of MARCO as recombinant protein or purified from tissues as well as for the generation of antibodies against the protein itself, and for the use of such antibodies to detect the protein in tissue, cell or fluid samples, or to interfere with the function of the receptor.
  • Macrophages are bone marrow-derived cells that form an important part of the host defense system. They play a role in physiological as well as pathological processes, such as inflammation, fibrosis atherogenesis, and tumor invasion.
  • Macrophages are relatively large (10-20 ⁇ m), long-lived, amoeboid, phagocytic and pinocytotic cells present in blood, lymph and other tissues. They are derived from monocytes which form a pool of precursors migrating from blood into peripheral tissues such as liver, spleen, lung, lymph nodes, peritoneum, skin, brain and bone, where they differentiate into macrophages with organ specific features. Macrophages play important roles in host resistance to a variety of pathogenic microorganisms, having important functions in, for example, phagocytosis, inflammation, antibody formation, cell-mediated cytotoxicity and delayed hypersensitivity.
  • macrophages have their ability to recognize, internalize and destroy a variety of foreign and endogenous substances and, thus, to function as scavengers that engulf pathogenic organisms, such as bacteria, parasites and viruses. Macrophages also remove extravasated blood cells or dead cells in tissues and, thereby, participate in the maintenance of tissues. Furthermore, macrophages are thought to play a role in immune response by presenting foreign antigens (i.e., are antigen- presenting cells) to lymphocytes. The macrophages have been shown to be able to bind "nonself" pathogens directly, or they recognize pathogens as foreign because they have been coated by antibodies or complement. The exact recognition mechanism is unknown, but it has been proposed that receptors with broad binding specificity are used to discriminate between self and nonself.
  • Scavenger receptors are macrophage cell membrane proteins that can bind a variety of substances and facilitate their uptake and removal from blood or connective tissue (see Krieger and Hertz, Ann. Rev. Biochem. 63, 601-637, 1994).
  • the macrophage scavenger receptors have been suggested to play a role in the binding of foreign antigens, in addition to their apparently important role in atherogenesis. These receptors have unusually broad ligand binding specificity and, thus, differ from many other cell surface receptors.
  • Scavenger receptors of types I and II are trimeric membrane proteins with a small N-terminal intracellular domain, a transmembrane domain, and an extracellular portion containing a short spacer domain, an ⁇ -helical coiled coil domain, and a short triple-helical coUagenous domain (Krieger and Hertz, Ann . Rev . Biochem . - 63 , 601 -637 , 1 994 ) .
  • the type I scavenger receptor differs from the type II scavenger receptor in that it contains an additional C- terminal cysteine-rich domain.
  • These receptors which are present in macrophages in diverse tissues, such as liver and lung, have been shown to bind a variety of ligands such as chemically modified lipoproteins and albumin, polyribonucleotides, polysaccharides, phospholipids, asbestos etc. It has been proposed that the scavenger receptors play a key role in the development of atherosclerosis where they mediate macrophage uptake of modified low density lipoproteins (LDL) in arterial walls.
  • LDL low density lipoproteins
  • the scavenger receptors are likely to function in host defense as some forms of gram-negative bacterial endotoxin and gram- positive bacteria can serve as their ligands.
  • the coUagenous domain of the scavenger receptor has been shown to mediate the binding activities assigned to these receptors.
  • the coUagenous domain of the scavenger receptor is a triple helix formed by three chains which contain 24 consecutive Gly-Xaa-Yaa-triplets.
  • Gly-Xaa-Yaa-triplets are the hallmark of the ⁇ chains of collagens, which are a family of extracellular proteins constituting the major structural proteins of the extracellular matrix.
  • proteins without structural functions that contain coUagenous domains.
  • As the scavenger receptors most of those belong to the host defense mechanisms, such as complement factor C1q, conglutinin, mannose binding proteins, and pulmonary surfactant associated proteins. All these proteins are thought to participate in the removal of extracellular debris such as pathogenic material.
  • enzymes such as acetyl cholinesterase and bacterial pullulanase contain coUagenous domains.
  • the present invention is directed to processes for isolating and identifying the nucleotide sequence of a gene for a novel macrophage receptor with coUagenous structure, termed "MARCO" by the applicants.
  • the new macrophage receptor with a coUagenous domain binds gram positive and negative bacteria and acetylated LDL.
  • the invention relates to the nucleotide sequence for MARCO identified by the process of the invention and the isolated and purified polypeptide chain encoded by such a nucleotide sequence.
  • the invention provides for the use of the identified nucleotide sequence, or DNA fragments thereof, to prepare DNA or RNA probes, radiolabeled, enzyme-labeled, chemiluminescence-labeled, avidin or biotin-labeled, or containing modified nucleotides, incorporated into a self- replicating vector, a viral vector, linear or circular, to detect the presence of the gene or mutations in the gene which can directly or indirectly produce disease.
  • the invention also relates to the use of gene fragments from human genomic or cloned DNA for detection and analysis of the gene .
  • the invention provides for the use of identified DNA sequence to correct for gene defects leading to mutations causing a malfunctioning MARCO.
  • the instant invention also provides for methods for detecting the presence of specific MARCO mRNA in cells and tissues with an effective amount of nucleic acid probe, which probe contains a sense or antisense of MARCO mRNA sequence.
  • the instant invention also provides for methods for generating the MARCO protein as recombinant protein or fragments thereof by inserting the gene into micro-organisms and expressing it in micro-organisms or eukaryotic cells.
  • the invention provides for the synthesis of peptides from the MARCO polypeptide chain based on the amino acid sequence derived from the coding sequence of the cloned gene.
  • the present invention also provides for the generation of immunoreactive antibodies, made against the MARCO protein or parts thereof, including synthetic peptides, that specifically detect the receptor protein and which can be used to detect the expression of the receptor in tissue, cell and fluid samples as well as for interfering with the binding of ligands such as bacteria to the macrophage receptor.
  • the present invention involves several different embodiments.
  • the invention provides clones coding for the entire mouse MARCO polypeptide chain.
  • the invention is directed, in particular, to a full-length mouse cDNA clone Maf-6.
  • the invention provides for nucleotide sequences which encode the entire mouse amino acid sequences of the MARCO polypeptide.
  • the invention provides for vectors containing parts of the mouse Maf-6 cDNA for the production of recombinant proteins.
  • the invention also provides for two types of polyclonal antibodies recognizing the intra and extracellular domains of murine MARCO, respectively.
  • FIG. 1 shows restriction map of a cDNA clone (Maf-6) coding for the mouse MARCO subunit polypeptide chain. The 5'- and 3'-end orientations are indicated. Restriction endonuclease cleavage sites EcoRI (E) and Pst I (P) are shown. The translation initation site (ATG) and termination (TGA) sites and a potential polyadinylation site (AATAAA) are shown as well as a poly (A) tail (AAAAAA) . Scale in base pairs is shown below the clone.
  • FIGS. 2A and B show the nucleotide sequence (first line) of the murine MARCO chain cDNA (SEQ ID NO: 1) and its predicted (deduced) amino acid sequence (second line) shown with the one letter code (SEQ ID NO: 2).
  • the tentative transmembrane domain II is indicated by an underline and cysteine residues and the two potential glycosylation sites are circled.
  • the 3' end termination codon is indicated by "ter”.
  • a putative polyadinylation signal AATAAA is double-underlined.
  • FIG. 3 depicts the predicted tertiary structure of the macrophage MARCO receptor.
  • the MARCO receptor is a trimeric protein containing an N-terminal end intracellular domain I, a transmembrane domain II, and an extracellular domain consisting of a "spacer" domain III, a coUagenous domain IV with 89 Gly-Xaa-Yaa-repeat sequences interrupted at one location and a C-terminal end cysteine-rich domain V.
  • FIGS. 4A-4H show the results of in si tu hybridization analyses of MARCO expression and comparison of immunolocalization of MARCO and macrophage R-TR9 and MOMA-1 antigens in mouse spleen and lymph node.
  • Hybridization with the MARCO antisense probe (A,B) showed strong signals in cells located in a circle-like array in the marginal zone (mz) between the white (w) and red (r) pulps.
  • Immunostaining with an antibody against the intracellular domain I of MARCO (C) and with the ER-TR9 antibody specific for marginal zone macrophages (D) showed codistribution of antigens.
  • Double- staining with MARCO (blue) and MOMA-1 (red) antibodies showed some marginal zone macrophages positive for MARCO, but negative for ER-TR9 (E).
  • Double-staining with MARCO (blue) and MOMA-1 (red) antibodies shows respectively, staining of marginal zone macrophages and metallophilic macrophages lining the marginal sinus (F).
  • Hybridization with the MARCO antisense probe (G and H, dark and light fields, respectively) showed strong signals in cells located in the meduallary cord region of lymph node. E, capsule; mc, medullary cord; pc, paracortex. Bars in A, 800 ⁇ m; in C, D, E and F, 35 ⁇ m; in G and H, 400 ⁇ m.
  • FIGS. 5A-5B shows localization of the MARCO protein on the surface of cultured IC-21 macrophages using field emission scanning immunoelectron microscopy carried out with a polyclonal antibody against the extracellular domain.
  • Fig. 5A intense gold label can be seen on the cell surface proper and pseudopodia (x10,000).
  • Fig. 5B is magnification (x50,000) of pseudopodia. No label was observed with antibodies against domain I (not shown) .
  • FIG. 6 demonstrates binding of MARCO antibodies to spleen marginal zone macrophages in vivo.
  • Rabbit antiserum to the extracellular domain V of MARCO was injected intravenously into mouse after which tissue was removed and processed for staining using a FITC-labeled anti-rabbit IgG. The label was confined to marginal zone (mz) macrophages located between the red (r) and white (w) pulps. Antibodies against domain I did not bind cells (not shown).
  • FIGS. 7A-7B show immunoprecipitation and immunoblot analyses of MARCO protein from mouse tissues and transfected COS cells.
  • Fig. 7A protein from spleen and kidney was extracted, immunoprecipitated with antisera against recombinant domains I (N) or V (C) of MARCO, electrophoresed on a 5 % gel without reduction and immunoblotted.
  • the antisera precipitated a 210,000 dalton protein from spleen (lanes 1 and 2), while no proteins were precipitated from the kidney (lanes 3 and 4) extract.
  • the broad band of about 160,000 daltons seen in both spleen and kidney samples is immunoglobulin.
  • FIGS. 8A-8F illustrate binding of fluorescein-labeled E. coli , S. aureus and Zy osan A (S. cerevisiae) bacteria to MARCO receptors on cells transfected with full-length cDNA.
  • Transfected COS cells or IC-21 macrophages were incubated with FITC-labeled S. aureus (A, D), E. coli (B, E) and Zymosan A (C, F) and the MARCO expressing COS cells were visualized by immunostaining with MARCO antibodies and a rhodamine labeled secondary antibody.
  • the IC-21 cells were stained with ethidium bromide.
  • FIG. 9 illustrates how antibodies against the extracellular domains IV and V of MARCO inhibit the biding of FITC-labeled Staphylococcus aureus bacteria to COS cells transfected with full-length MARCO cDNA and expressing native MARCO receptor.
  • FIGS. 10A-10B show binding of Dil-labeled AcLDL to COS cells expressing the MARCO receptor.
  • the MARCO expressing cell were incubated with Dil-AcLDL (5 ⁇ g/ml) and visualized with MARCO antiserum and a FITC-labeled secondary antibody.
  • Immunopositive COS cells (A) readily bound Dil-AcLDL (B) .
  • the applicants have discovered a novel gene encoding for a previously unknown protein.
  • the DNA-derived amino acid sequence of the protein is unique, not existing in the available data bases.
  • the protein is a novel murine plasma associated protein expressed postnatally by subpopulations of macrophages.
  • the new polypeptide chain (SEQ ID NO: 2), which was shown to be a one of three, presumably identical subunit chains of a macrophage membrane receptor with a coUagenous structure, has been designated as "MARCO" for macrophage receptor-collagenous.
  • the MARCO polypeptide chain was discovered by the isolation and nucleotide sequencing of cDNA clones which were identified during the screening of a mouse macrophage cDNA library with a human type XIII collagen DNA probe. This screening yielded several overlapping clones coding for a previously undescribed coUagenous sequence, and rescreening of the same library with one of the cDNA inserts yielded new clones one of which, Maf-6 (Fig. 1), spanned a 1.8 kb sequence.
  • the sequence of Maf-6 (SEQ ID NO: 1) contained a 159 bp 5'- end untranslated region, a 1554 bp open reading frame, followed by an over 156 bp 3'-end untranslated region containing a TGA translation stop codon, a putative AATAAA polyadenylation signal and a poly(A) tail (Figs. 1 and 2).
  • the sequence surrounding the putative initiator methionine codon ATG does not agree completely with the Kozak consensus sequence, but it can be designated as strong translation initiation site when considering positions -3 and +4 (Kozak, M., The scanning model for translation: An update, J. Cell. Biol. 108, 229-241 (1989)).
  • the amino acid sequence indicated the presence of several distinct domains.
  • the open reading frame starts with an ⁇ 50- residue rather hydrophilic domain I which starts with the initiator methionine and contains one cysteine. See Figs. 2 and 3. Therefore, this protein does not contain a hydrophobic signal peptide-like sequence characteristic for secreted proteins.
  • Domain II has an ⁇ 25-residue hydrophobic sequence, which is followed by a hydrophilic domain III containing 75 residues, including two cysteine residues. Domain III also has two putative N-glycosylation sites (Fig. 2). The sequences of domains I, II and III are each unique.
  • Domain IV has a 270-residue coUagenous sequence characterized by 89 Gly-Xaa-Yaa triplets interrupted at one location (residues 174-176) by the sequence Ala-Glu-Lys.
  • the C-terminal globular domain V which has 99 residues, six of which are cysteine.
  • the sequence of this domain showed 48.9 % sequence identity with the C-terminal domain of scavenger receptor type I (Krieger and Hertz, 1994).
  • the coUagenous domain IV the other domains did not show significant ho ology with scavenger receptors or other known proteins.
  • the novel coUagenous macrophage receptor with coUagenous structure described here is referred to by the applicants as MARCO.
  • RNA isolated from several mouse tissues were freshly isolated peritoneal macrophages and cultured cells. Using mRNA from adult mice, strong signals were observed with RNA from spleen and peritoneal macrophages, but not in other tissues, including liver (data not shown).
  • MARCO is expressed in established macrophage cell lines using Northern analysis with mRNA isolated from a cultured macrophage cell line IC-21 (ATCC TIB 186), and the results revealed intense expression of an about 1.8 kb transcript (not shown).
  • the antibodies decorated the cell surface quite evenly and they also bound strongly to pseuodopodia which could protrude quite long distances from the cell membrane.
  • transmission im unoelectron microscopy was carried out with the antibodies and this revealed that MARCO is associated with the plasma membranes.
  • MARCO is a membrane protein, and that within the plasma membrane domain I is located intracellulariy and domain V extracellularl .
  • MARCO is a trimeric protein with a triple-helical domain similar to those in coUagenous proteins, based on the fact that the MARCO subunit chain contained a 270-residue long Gly-Xaa-Yaa-repeat containing sequence. Furthermore, the presence of several cysteines in the polypeptide suggested that the chains might be disulfide- linked in such a trimer. In order to examine this, the applicants extracted protein from intact mouse spleen and kidney (negative control) tissues, and carried out immunoprecipitation with the antibodies against domains I or V of MARCO, followed by immunoblotting as more particularly described in the Examples below. This study revealed that when the spleen extract .
  • Pulse-labeled immunoprecipitated MARCO extracted from the transfected cells was electrophoresed on SDS-PAGE without reduction and compared with MARCO immunoprecipitated from a spleen tissue extract.
  • the results showed that the sizes of tri eric MARCO proteins from the COS cells (Fig. 7B, lane 1) and spleen (Fig. 7A, lanes 1 and 2) corresponded to each other.
  • COS cells transfected with a construct containing MARCO cDNA in the wrong orientation did not reveal specific bands after immunoprecipitation (Fig. 8B, lanes 2 and 6). Together, the labeling data demonstrated that the transfected cells were able to synthesize single MARCO chains and assemble them into disulfide-bonded homotrimers.
  • the marginal zone macrophages in the spleen have been proposed to play a key role in the host-defense system by recognizing and phagocytosing blood pathogens such as bacteria and yeast.
  • the cells can selectively take up neutral polysaccharides present on bacterial walls.
  • MARCO cultured transfected COS cells, and IC-21 macrophages used as positive control cells, were incubated with several fluorescein-labeled bioprobes.
  • transfected COS cells expressing MARCO were incubated with labeled E. coli and 5. aureus bacteria, specific binding was seen to cells which were immunopositive with MARCO antibodies (Fig. 8A, B). In contrast, labeled S.
  • S. aureus could be inhibited efficiently by antiserum (not shown) and IgG (Fig. 9) raised against domains IV and V. Binding of E. coli could also be inhibited by these antibodies (not shown).
  • MARCO plasma membrane-bound macrophage receptor with coUagenous structure
  • Type I macrophage receptor contains ⁇ -helical and collagen-like coiled coils, Nature 343, 531-535 (1990)) which also is a macrophage specific protein.
  • MARCO is clearly a distinct gene product with somewhat different binding properties than the scavenger receptor.
  • MARCO is a Membrane-Bound Trimeric Protein Based on the deduced amino acid sequence of the MARCO polypeptide which contains a 270-residue Gly-Xaa-Yaa-repeat sequence, it could be predicted that MARCO is a trimeric protein where this domain folds into a triple helix similar to that of collagens. This assumption gained support by experiments showing that MARCO extracted from both spleen tissue and transfected COS cells had a molecular weight of about 210,000 on SDS-PAGE without reduction. These experiments also demonstrated that the subunit chains are disulfide-bonded.
  • the calculated molecular weight of a MARCO trimer containing unprocessed chains would be 160,000, but glycosylation of one or both of the two potential glycosylation sites in the MARCO polypeptides could explain a molecular weight of over 200,000 as determined by SDS-PAGE.
  • the pulse-chase and Tunicamycin labeling studies carried out in this study supported this assumption.
  • the triple helix of domain IV in MARCO is likely to have a "kink” or "hinge” as has been shown to be the case in collagens with interrupted triple helices such as type IV collagen (Hudson, B.G., Reeders, S.T., and Tryggvason, K., Type IV collagen: Structure, gene organization and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis, J. Biol. Chem. 15, 26033-26036, (1993)).
  • the MARCO molecules in vivo are homo- or heterotrimers, but applicants' experiments demonstrated that homotrimers can be formed in transfected COS cells from the MARCO subunit chain cloned in this study.
  • MARCO is not a secreted protein, as it does not contain a typical signal peptide sequence as in the case for the scavenger receptors.
  • the hydrophobic sequence of domain II which resembles that of the single transmembrane domain of the scavenger receptor chains further indicated that MARCO is a membrane protein and this was confirmed in various immunological studies which clearly localized the protein to the plasma membrane, but also to intracellular membranes.
  • the fact that grains were seen in association with intracellular membranes in immunoelectron microscopy may not necessarily mean that MARCO functions intracellulariy, as it is possible that the intracellular membrane association is due to newly synthesized MARCO which is being transported out of the cell or, alternatively, internalized MARCO.
  • the primary structure of the MARCO subunit chain characterized here has higher similarity with the scavenger receptor chains than with any of the chains of structural collagens or other proteins with coUagenous domains, including C1q, conglutinin, mannose binding proteins, pulmonary surfactant associated proteins, acetyl cholinesterase and bacterial pullulanase (Reid, K.B.M., Lowe, D.M., and Porter, R.R., Isolation and characterization of Clq, sub-component of the first component of complement from human and rabbit sera, Biochem. J. 130, 749-763 (1972); Mays, C.
  • MARCO is, indeed, an integral trimeric membrane molecule, where each chain has a single membrane- spanning domain and an N-terminal cytoplasmic domain I as in the scavenger receptor.
  • the orientation of MARCO was verified by immunohistochemical and FESEM analyses which clearly demonstrated that domain V is extracellular and domain I intracellular.
  • the 75-residue extracellular domain III of the MARCO chain which corresponds to the 33-residue domain III in the scavenger receptor chains, probably participates in a "spacer" domain between the plasma membrane and the rod-like triple-helical domain IV of MARCO.
  • the triple-helical domain IV of MARCO differs substantially from the coiled coil region formed by domains IV and V of the scavenger receptor.
  • Domain IV of MARCO forms a triple-helical coUagenous domain interrupted at one site by an Ala-Glu-Lys sequence, while the scavenger receptor has first a noncollagenous ⁇ -helical coiled coil followed by a classical coUagenous triple helix which, however, is considerably shorter than that of MARCO.
  • the C-terminal end domains V and VI of MARCO and scavenger receptor type I, respectively, are quite homologous, each containing six cysteine residues with similar spacing. This scavenger receptor cysteine-rich motif (SRCR domain) has been found in a number of other proteins.
  • SRCR- domain-containing proteins are expressed on the surfaces of cells associated with the immune system and host defence functions (T cells, B cells and macrophages) or are secreted and known or suspected of being involved with host defence (Resnick, D. , Pearson, A., and Krieger, M. , The SRCR superfamily: a family reminiscent of the Ig superfamily, Trends Biochem. Sci. 19, 5-8 (1994)).
  • T cells, B cells and macrophages The SRCR superfamily: a family reminiscent of the Ig superfamily, Trends Biochem. Sci. 19, 5-8 (1994)).
  • this sequence is highly conserved between MARCO and scavenger receptor, the sequence identity being 48.9 % and sequence similarity 61.5 % when conserved amino acid substitutions are taken into account.
  • MARCO MARCO-induced immunological reactions. It also emphasizes the heterogeneity within macrophage populations and the compartmentalization of the lymphoid system.
  • the marginal zone macrophages of the spleen in which MARCO is highly expressed form, in many respects, a very special population. These large macrophages are strategically positioned in the anatomical compartment of the spleen where the bloodstream leaves the small arterioles into the "open" venous system (Kraal, G.
  • MARCO MARCO molecule probably has different functions as it is present in different types of macrophages. For example, MARCO was not found in liver or lung tissues. However, as scavenger receptors, MARCO binds acetylated LDL and bacteria, but it differs by not binding yeast. The restricted expression of the MARCO receptor on macrophages capable of binding and possibly taking up acetylated LDL and located at sites in the spleen where they are in continuous contact with the blood stream points to a significant role in the clearance of serum components.
  • MARCO plays an important role in the host defense system and ho eostasis of the body.
  • a mouse macrophage cDNA library in ⁇ gtl1 (Clontech ML1005) was screened with a human type XIII collagen DNA. Clones were screened to purity with 32 P-labeled probes at low stringency conditions at +37 °C in 5xSSC, 5xDenhart's, 0.1 % SDS, 50 % formamide, 200 mg/ l salmon sperm DNA. Filters were washed with 0.2xSSC, 0.1 % SDS at +42 °C.
  • Positive clones were isolated and subcloned into pUC18/19- or M1318/19-vectors with standard methods, and sequenced from both strands with the dideoxynucleotide chain-termination procedure using Sequenase enzyme (United States Biochemicals) . Either universal primers or specific oligonucleotide primers were used in the sequencing.
  • RNA from tissues liver, kidney, spleen, lung, brain and thymus
  • RNA was isolated directly from cultured cells or from total RNA with a slight modification of the Fast Track RNA isolation kit method (Invitrogen) by oligo dT cellulosa (Pharmacia).
  • mRNA was electrophoresed on a 1.0 % agarose gel in the presence of formaldehyde.
  • RNA was transferred to nitrocellulose filters, which were hybridized with a MARCO cDNA insert labeled with 32 P-dCTP by random priming. Prehybridization and overnight hybridization were done at +42 °C in 5xSSC, 5xDenhart's, 0.1 % SDS, 50 % formamide, 200 mg/ml salmon sperm DNA solution. Membranes were washed in 2xSSC, 0.1 % SDS +42 °C.
  • si tu hybridization was carried out on whole 14 to 17 day- old mouse embryos and on lung, liver spleen, lymph nodes, kidney and heart tissues of 9-day-old pups, as well as on bone marrow, intestine, lung, liver, spleen, lymph nodes, kidney and thymus of adult mice.
  • Tissues were dissected in phosphate-buffered saline, pH 7.3 and fixed in paraformaldehyde at +4 °C for 1 h or overnight, dehydrated, and embedded in paraffin wax. Sections of 7 ⁇ m were placed on silanized glass slides and stored at +4 °C until used.
  • RNA probes DNA fragments (nucleotides 65-398 and 2211-1672 in Fig.2) were amplified by PCR using the Maf-6 cDNA clone as template. PCR primers contained restriction sites for subcloning into pSP64 and pSP65 plasmid vectors (Promega). The labeling of probes and in si tu hybridization were performed (Wilkinson, D.G. , and Green, J., In situ hybridization and the three dimensional reconstruction of serial sections. In Postimplantation mammalian embryos, A.J. CQPP and D.L. Cockroft. eds. (Oxford: OUP) . pp. 155-171 (1990)).
  • the plasmids were first linearized and [ 35 S]-UTP -labeled (1OOOCi/nmol, Amersham) probes were transcribed from the SP6 promoter.
  • the probes were fractionated with Sephadex G-50 (Pharmacia), precipitated with ethanol, mixed with hybridization mixture, and placed on the pretreated sections.
  • the sections were incubated overnight at +50 °C, washed under high stringency condition, and dipped in autographic emulsion (Kodak NTB2). After exposure for 11 days, the emulsion was developed and the sections were stained with he atoxylin and mounted.
  • domains of the MARCO polypeptide were expressed as glutathione S-transferase (GST) fusion proteins in the pGEX-1 ⁇ T vector (Pharmacia) in E. coli .
  • GST glutathione S-transferase
  • DNA fragments encoding the putative extracellular domain IV and V (residues 369-518, Fig. 2) and intracellular domain I (residues 1-50, Fig. 2) of the MARCO polypeptide were generated by polymerase chain reaction (PCR) using primers containing restriction sites for cloning into the pGEX-1 ⁇ T vector (Pharmacia). Sequences were confirmed by DNA-sequencing.
  • Fusion proteins produced in bacteria were purified using glutathione Sepharose 4B (Pharmacia) and eluted with 5 mM glutathione.
  • Purified MARCO polypeptides were mixed with Freund's adjuvant (Difco), and used for immunization of rabbits. Antisera were used after the third booster.
  • IgGs were first purified by protein A Sepharose (Pharmacia) and then further purified by negative immunoabsorption from unspecific antibodies against the GST- protein and E. coli proteins using GST-E. coli total protein lysate coupled to CNBr-activated Sepharose 4B (Pharmacia).
  • crysections were first incubated with the antibody, and then with horseradish peroxidase
  • the antigen was precipitated using polyclonal antisera or purified IgG against MARCO and incubated with protein A- Sepharose (Pharmacia).
  • the protein A-sepharose-IgG complex was washed with NET buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % Nonidet P-40, 1 mM EDTA, pH 8, 0.25 % gelatin and 0.02 % sodium azide) and then with 10 mM Tris-HCl, pH 7.5, 0.1 % NP-40 solution, and heated in sample buffer at 95° C in the presence or absence of 5 % mercaptoethanol prior SDS- PAGE.
  • NET buffer 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % Nonidet P-40, 1 mM EDTA, pH 8, 0.25 % gelatin and 0.02 % sodium azide
  • the membranes were blocked with 3 % milk powder in TBS buffer (25 mM Tris-HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl) followed by incubation with MARCO antiserum diluted 1:50 - 1:100 in TBS buffer. After washings with TBS buffer the membranes were incubated with alkaline- phosphatase-conjugated anti-rabbit IgG (Sigma), washed and developed with nitroblue tetrazolium/5-bromo-4-chloro-3- indolyl phosphate.
  • TBS buffer 25 mM Tris-HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl
  • IC-21 and COS-1 were from ATCC. IC-21 cells were grown in RPMI 1640 medium and COS-1 cells in high glucose (4.5 g/1) Dulbecco's Modified Eagle's medium (Gibco laboratories) both mediums were supplemented with 10 % fetal calf serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 75 mg/ml ascorbate.
  • high glucose 4.5 g/1
  • Dulbecco's Modified Eagle's medium Gibco laboratories
  • fetal calf serum 2 mM L-glutamine
  • penicillin 100 IU/ml penicillin
  • 75 mg/ml ascorbate 75 mg/ml ascorbate.
  • a cDNA fragment containing the entire coding region of MARCO with the authentic translation initiation sequence was generated by oligonucleotide-primed polymerase chain reaction and its sequence was confirmed by DNA-sequencing.
  • the product was cloned into the pSG5 expression vector (Green, S., Isseman, I., and Sheer, E., A versatile in vivo and in vi tro eukaryotic expression vector for protein engineering, Nucl. Acid. Res. 16, 399 (1988)) using Bgl II restriction sites engineered into the primers. Additionally, a construct made with a 5'-PCR primer containing an additional consensus sequence GCCGCCACCATGG (Kozak, M, The scanning model for translation: An update. J. Cell. Biol. 108, 229-241 (1989)) was made for more effective initiation of translation. A construct containing the coding region in the opposite orientation (3'-5') was used as a control.
  • COS-1 cells were plated at 0.7 x10 6 cells per 90 mm tissue culture dish. The cells were transfected overnight by the calcium phosphate method (Gorman, C, High efficiency gene transfer into mammalian cells. In DNA cloning. Volume II, A practical approach, D.M. Glover, ed (Oxford: IRL press), pp. 143-161 (1985)) using 20 ⁇ g DNA isolated with CsCl gradient centrifugation. After 18 hrs the calcium phosphate precipitate was removed, and cells used for immunostaining or binding assays were harvested with trypsin and replated.
  • IC-21 macrophages positive control
  • transfected COS cells cultured on coverslips were incubated in the culture medium at +37 °C with fluorescent labeled ligand candidates (Molecular Probes Ine); with FITC-labeled BioParticles, Escherichia coli , Staphylococcus aureus and Zymosan A ( Saccharomyces cerevisiae) for 1 hour, and with Dil (1,1 '-dioctadecyl-3,3, 3' ,3 '-tetramethyl-indocarbocyanine perchlorate)-labeled AcLDL (5 mg/ml) for 3-5 hrs.
  • Bio Particles and cells were incubated in 50:1- 100:1 ratios. In the Zymosan A binding studies higher particle amounts and longer incubation times were also tested. Following incubation the cells were rinsed five times with PBS solution, fixed with 4 % paraformaldehyde or with ethanol for 10 minutes, and then immunostained using IgG against MARCO polypeptides and FITC- or rhodamine-labeled secondary antibodies as described in the immunofluorescence and confocal microscopy paragraph above. As negative controls, COS cells transfected with a plasmid containing cDNA in the wrong orientation were used.
  • Binding inhibition studies were carried out by adding normal rabbit IgG and MARCO anti-rabbit IgG (25-500 ⁇ g/ml) or preimmune and anti-MARCO sera at 1/10-1/100 dilutions prior to the addition of ligands. Bound bacteria were counted from one hundred cells positive with anti-MACRO antibodies, each experiment being carried out in triplicates.
  • Domain III also has two putative N- glycosylation sites (Fig..2).
  • the sequences of domain I, II and III are each unique, with no significant homology with sequences in the EMBL and Swiss protein data bases.
  • Domain IV has a 270-residue coUagenous sequence characterized by 89 Gly-Xaa-Yaa triplets interrupted at one location (residues 174-176) by the sequence Ala-Glu-Lys.
  • the C-terminal globular domain V which has 99 residues, six of which are cysteine.
  • the sequence of this domain showed 48.9 % sequence identity with the C-terminal domain of scavenger receptor type I.
  • the other domains did not show significant homology with scavenger receptors or other known proteins.
  • MARCO The initial cDNA clones for MARCO were isolated from a macrophage cDNA library. In order to obtain an overall picture of the spatial expression of MARCO, Northern analyses were first carried out with RNA isolated from several tissues, freshly isolated peritoneal macrophages and cultured cells. Using mRNA from adult mice, strong signals were observed with RNA from spleen and peritoneal macrophages, but not in other tissues, including liver (data not shown).
  • MARCO is expressed in established macrophage cell lines.
  • applicants carried out Northern analysis with mRNA isolated from a cultured macrophage cell line IC-21 (ATCC TIB 186). These cells exhibited intense expression of an about 1.8 kb transcript (not shown).
  • IC-21 transformed macrophages were processed for field emission scanning electron microscopy (FESEM) of the cell surface and reacted with antisera against the putative extracellular C-terminal or intracellular N-terminal domains followed by incubation with a gold-labeled second antibody.
  • the antibody against the C-terminal domain V readily bound to the cell surface (Figs. 5A and 5B), while the antibody against the N-terminal domain I did not (data not shown).
  • the antibodies decorated the cell surface quite evenly and they also bound strongly to pseuodopodia which could protrude quite long distances from the cell membrane.
  • Transmission immunoelectron microscopy revealed gold particles particularly associated with the plasma membranes, but also to some extent in intracellular membranes (not shown). Together, these results demonstrated that MARCO is a membrane protein, and that within the plasma membrane domain I is located intracellulariy and domain V extracellularly.
  • MARCO Polypeptide Chains Form Disulfide-linked Trimers in Vivo The presence of a 270-residue long Gly-Xaa-Yaa-repeat containing sequence indicated that MARCO is a trimeric protein with a triple-helical domain similar to those in coUagenous proteins. Furthermore, the presence of several cysteines in the polypeptide suggested that the chains might be disulfide-linked in such a trimer. In order to address this question, we extracted protein from intact mouse spleen and kidney (negative control) tissues, and carried out immunoprecipitation with the antibodies against domains I or V of MARCO, followed by immunoblotting (Sambrook, J.
  • COS cells which normally do not express MARCO, were transfected with full-length cDNA to study glycosylation of the chains and also if native MARCO trimers can be formed with a single type of chains. Furthermore, labeling studies were carried out in the presence of Tunicamycin in order to examine if the minor heterogeneity of specifically immunoprecipitated bands might be due to differences in degree of glycosylation. Incubation with Tunicamycin, which inhibits N-glycosylation, revealed a MARCO chain with a size of " 50,000 daltons which agrees well with the calculated size based on the amino acid sequence predicted from the cDNA (Fig. 7B, lane 5).
  • Pulse-labeled immunoprecipitated MARCO extracted from the transfected cells was electrophoresed on SDS-PAGE without reduction and compared with MARCO immunoprecipitated from a spleen tissue extract.
  • the results showed that the sizes of trimeric MARCO proteins from the COS cells (Fig. 9B, lane 1) and spleen (Fig. 7A, lanes 1 and 2) corresponded to each other.
  • the marginal zone macrophages in the spleen have been proposed to play a key role in the host-defense system by recognizing and phagocytosing blood pathogens such as bacteria and yeast.
  • the cells can selectively take up neutral polysaccharides present on bacterial walls.
  • cultured transfected COS cells, and IC-21 macrophages used as positive control cells were incubated with several fluorescein-labeled bioprobes.
  • transfected COS cells expressing MARCO were incubated with labeled E. coli and S. aureus bacteria, specific binding was seen to cells which were immunopositive with MARCO antibodies (Fig. 8 A,B).
  • S. aureus could be inhibited efficiently by antiserum (not shown) and IgG (Fig. 9) raised against domains IV and V. Binding of E. coli could also be inhibited by these antibodies (not shown).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des processus permettant d'isoler et d'identifier la séquence nucléotidique d'un gène destinée à un nouveau récepteur de macrophage à structure collagène, dénommé 'MARCO'. Le nouveau récepteur de macrophages à domaine collagène se lie à des bactéries Gram positif et Gram négatif et à des LDL acétylées. L'invention concerne également la séquence nucléotidique destinée à MARCO, identifiée lors du processus, ainsi que la chaîne polypeptidique isolée et purifiée codée par cette séquence.
PCT/FI1996/000091 1995-02-21 1996-02-19 Sequence d'adn isolee destinee a un nouveau recepteur de macrophage a domaine collagene et chaine polypeptidique codee par cette sequence WO1996026219A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU47196/96A AU4719696A (en) 1995-02-21 1996-02-19 Isolated dna sequence for a novel macrophage receptor with a collagenous domain and the polypeptide chain encoded by such a sequence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/392,367 US5691197A (en) 1995-02-21 1995-02-21 Isolated DNA sequence for a novel macrophage receptor with a collagenous domain
US08/392,367 1995-02-21

Publications (1)

Publication Number Publication Date
WO1996026219A1 true WO1996026219A1 (fr) 1996-08-29

Family

ID=23550297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1996/000091 WO1996026219A1 (fr) 1995-02-21 1996-02-19 Sequence d'adn isolee destinee a un nouveau recepteur de macrophage a domaine collagene et chaine polypeptidique codee par cette sequence

Country Status (3)

Country Link
US (2) US5691197A (fr)
AU (1) AU4719696A (fr)
WO (1) WO1996026219A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808899A2 (fr) * 1996-05-23 1997-11-26 Smithkline Beecham Corporation Récepteur piégeur "Marco Scavenger" humain (HMarcoSR)
WO1999014329A1 (fr) * 1997-09-19 1999-03-25 Incyte Pharmaceuticals, Inc. Recepteur macrophage humain de type marco

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444082T1 (de) 2000-10-16 2009-10-15 Cytoguide Aps Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005748A1 (fr) * 1988-11-15 1990-05-31 Massachusetts Institute Of Technology Proteine receptrice pure et anticorps pour celle-ci
WO1992014482A1 (fr) * 1991-02-22 1992-09-03 Massachusetts Institute Of Technology Traitement de l'endotoxemie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005748A1 (fr) * 1988-11-15 1990-05-31 Massachusetts Institute Of Technology Proteine receptrice pure et anticorps pour celle-ci
WO1992014482A1 (fr) * 1991-02-22 1992-09-03 Massachusetts Institute Of Technology Traitement de l'endotoxemie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIALOG INFORMATION SERVICE, File 154, Medline Dialog Accession No. 07119162, Medline Accession No. 90026162, LOOS M. et al., "The Biosynthesis of Clq, the Collagen-Like and Fc-Recognizing Molecule of the Complement System"; & BEHRING INST. MITT., (GERMANY, WEST), July 1989, (84), p32-41. *
DIALOG INFORMATION SERVICE, File 154, Medline Dialog Accession No. 09241455, Medline Accession No. 95171455, ELOMAA O. et al., "Cloning of a Novel Bacteria-Binding Receptor Structurally Related to Scavenger Receptors and Expressed in a Subset of Macrophages"; & CELL (UNITED STATES), 24 Feb. 1995, 80(4), *
PROC. NATL. ACAD. SCI. U.S.A., Volume 91, March 1994, DANA W. DUNNE et al., "The Type I Macrophage Scavenger Receptor Binds to Gram-Positive Bacteria and Recognizes Lipoteichoic Acid", pages 1863-1867. *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0808899A2 (fr) * 1996-05-23 1997-11-26 Smithkline Beecham Corporation Récepteur piégeur "Marco Scavenger" humain (HMarcoSR)
EP0808899A3 (fr) * 1996-05-23 1998-04-22 Smithkline Beecham Corporation Récepteur piégeur "Marco Scavenger" humain (HMarcoSR)
US5916766A (en) * 1996-05-23 1999-06-29 Smithkline Beecham Corporation Human marco scavenger receptor
US6197931B1 (en) 1996-05-23 2001-03-06 Smithkline Beecham Corporation Human marco scavenger receptor
WO1999014329A1 (fr) * 1997-09-19 1999-03-25 Incyte Pharmaceuticals, Inc. Recepteur macrophage humain de type marco

Also Published As

Publication number Publication date
US6063901A (en) 2000-05-16
AU4719696A (en) 1996-09-11
US5691197A (en) 1997-11-25

Similar Documents

Publication Publication Date Title
Elomaa et al. Cloning of a novel bacteria-binding receptor structurally related to scavenger receptors and expressed in a subset of macrophages
AU669474B2 (en) T-cadherin adhesion molecule
AU758627B2 (en) Stable hypoxia inducible factor-1 alpha and method of use
US5773268A (en) Chromosome 21 gene marker, compositions and methods using same
J. Blake et al. Apo-dystrophin-1 and apo-dystrophin-2, products of the Duchenne muscular dystrophy locus: expression during mouse embryogenesis and in cultured cell lines
JP3922726B2 (ja) 分化抑制剤
JP3779989B2 (ja) リンパ抗原ｃｄ３０
US5691197A (en) Isolated DNA sequence for a novel macrophage receptor with a collagenous domain
JP4011629B2 (ja) 新規セマフォリン遺伝子（ｉ）
US6552177B2 (en) EH domain containing genes and proteins
JP5709815B2 (ja) 脳型有機アニオントランスポーターとその遺伝子
EP0905239B1 (fr) Gène codant Afadin-1
US20040110934A1 (en) Human mitochondrial proteins and polynucleotides encoding the proteins
US5945305A (en) Nucleic acid encoding congenital heart disease protein and products related thereto
WO1998017795A1 (fr) Acide nucleique codant des proteines ds-cam et produits associes
US6960656B1 (en) Nucleic acid encoding DS-CAM proteins and products related thereto
PL188612B1 (pl) Oczyszczony i wyizolowany DNA, chimeryczny polinukleotyd, wektor ekspresyjny i komórka gospodarza transformowana tym wektorem
JP4223536B2 (ja) 脳型有機アニオントランスポーターとその遺伝子
JP2000060560A (ja) 偶蹄目エピモルフィン
JP2000093178A (ja) Ｄｄ１３遺伝子

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase